 Psychedelics-based company Enveric Biosciences NASDAQ:ENVB has closed its previously announced underwritten public offering of 20 million shares of its common stock and warrants to purchase up to 20 million shares of its common stock for gross proceeds of approximately 10 million, before deducting underwriting discounts and commissions and other offering expenses. Transaction Details Enveric granted the underwriter a 45-day option to purchase up to an additional 3 million shares of common stock andor warrants to purchase up to an additional 3 million shares of common stock at the public offering price, which the underwriter has partially exercised for warrants to purchase up to 3 million shares of common stock. 